These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 24143916)

  • 1. Immunotherapy for lung cancer: ongoing clinical trials.
    Declerck S; Vansteenkiste J
    Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune alterations in lung cancer - the new therapeutic approach].
    Domagała-Kulawik J; Osińska I
    Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
    Decoster L; Wauters I; Vansteenkiste JF
    Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
    Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
    Rolfo C; Sortino G; Smits E; Passiglia F; Bronte G; Castiglia M; Russo A; Santos ES; Janssens A; Pauwels P; Raez L
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1173-87. PubMed ID: 25148289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAGE A3 antigen-specific cancer immunotherapeutic.
    Peled N; Oton AB; Hirsch FR; Bunn P
    Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination therapy for non-small-cell lung cancer.
    Cuppens K; Vansteenkiste J
    Curr Opin Oncol; 2014 Mar; 26(2):165-70. PubMed ID: 24441502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic vaccines explored in patients with non-small cell lung cancer.
    Ma K; Tang YH
    Anticancer Agents Med Chem; 2014 Feb; 14(2):256-64. PubMed ID: 24237217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the immune system for the treatment of non-small-cell lung cancer.
    Brahmer JR
    J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emepepimut-S for non-small cell lung cancer.
    Corrales-Rodriguez L; Blais N; Soulières D
    Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
    Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
    Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.